Want to see ELV full AI Analyst Report?

Elevance Health (ELV) Stock Forecast & Price Target

2,913 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ELV Analyst Ratings

Moderate Buy

13 Buy

6 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Elevance

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$447.28

▲(38.45% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $447.28 with a high forecast of $498.00 and a low forecast of $364.00. The average price target represents a 38.45% change from the last price of $323.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"268":"$268","499":"$499","325.75":"$325.8","383.5":"$383.5","441.25":"$441.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":498,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$498.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":447.27777777777777,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$447.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":364,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$364.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[268,325.75,383.5,441.25,499],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,416.19,422.4830769230769,428.7761538461538,435.0692307692308,441.3623076923077,447.6553846153846,453.9484615384615,460.2415384615385,466.5346153846154,472.8276923076923,479.1207692307692,485.4138461538462,491.7069230769231,{"y":498,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,416.19,418.5813675213675,420.97273504273505,423.36410256410255,425.7554700854701,428.1468376068376,430.5382051282051,432.92957264957266,435.32094017094016,437.71230769230766,440.1036752136752,442.4950427350427,444.8864102564103,{"y":447.27777777777777,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,416.19,412.1753846153846,408.16076923076923,404.1461538461538,400.13153846153847,396.11692307692306,392.1023076923077,388.0876923076923,384.07307692307694,380.05846153846153,376.0438461538462,372.02923076923076,368.0146153846154,{"y":364,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":387.617,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269.009,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":312.094,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.593,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":312.369,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":324.659,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":338.358,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.083,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.29,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.169,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.028,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":416.19,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$498.00

Average Price Target$447.28

Lowest Price Target$364.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David S Macdonald

Truist Financial

$475

Buy

47.04%

Upside

Reiterated

07/16/26

Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist

David Windley

Jefferies

$391→$450

Buy

39.30%

Upside

Reiterated

07/16/26

Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)

Stephen Baxter

Wells Fargo

$492→$473

Buy

46.42%

Upside

Assigned

07/16/26

Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo

Kevin Fischbeck

Bank of America Securities

$460

Buy

42.39%

Upside

Reiterated

07/16/26

Fischbeck Reiterates Buy on Elevance Health, Keeps $460 Price Target Unchanged Amid Cautious Guidance and Improving Fundamentals

Michael Ha

Robert W. Baird

$331→$393

Hold

21.65%

Upside

Reiterated

07/16/26

Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird

Andrew Mok CFA

Barclays

$480→$457

Buy

41.46%

Upside

Reiterated

07/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (NYSE: ELV) and Pfizer (NYSE: PFE)

Amit Daryanani

Evercore ISI

―

Hold

―

Reiterated

07/15/26

Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health

Erin Wright

Morgan Stanley

$404

Hold

25.06%

Upside

Reiterated

07/15/26

Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook

Ben Hendrix

RBC Capital

$439→$424

Hold

31.25%

Upside

Reiterated

07/15/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)

Scott Fidel

Goldman Sachs

$370→$395

Hold

22.27%

Upside

Reiterated

07/15/26

Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs

Jason Cassorla

Guggenheim

$399→$455

Buy

40.85%

Upside

Reiterated

07/15/26

Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)

Ryan Langston

TD Cowen

$465

Buy

43.94%

Upside

Assigned

07/14/26

TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)

Ann Hynes

Mizuho Securities

$465→$470

Buy

45.49%

Upside

Reiterated

07/13/26

Mizuho Securities Keeps Their Buy Rating on Elevance Health (ELV)

Sarah James

Cantor Fitzgerald

$400→$450

Buy

39.30%

Upside

Reiterated

07/07/26

Elevance Health price target raised to $450 from $400 at Cantor FitzgeraldElevance Health price target raised to $450 from $400 at Cantor Fitzgerald

Lance Wilkes

Bernstein

$424→$482

Buy

49.20%

Upside

Reiterated

07/02/26

Elevance Health price target raised to $482 from $424 at BernsteinElevance Health price target raised to $482 from $424 at Bernstein

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David S Macdonald

Truist Financial

$475

Buy

47.04%

Upside

Reiterated

07/16/26

Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist

David Windley

Jefferies

$391→$450

Buy

39.30%

Upside

Reiterated

07/16/26

Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)

Stephen Baxter

Wells Fargo

$492→$473

Buy

46.42%

Upside

Assigned

07/16/26

Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo

Kevin Fischbeck

Bank of America Securities

$460

Buy

42.39%

Upside

Reiterated

07/16/26

Fischbeck Reiterates Buy on Elevance Health, Keeps $460 Price Target Unchanged Amid Cautious Guidance and Improving Fundamentals

Michael Ha

Robert W. Baird

$331→$393

Hold

21.65%

Upside

Reiterated

07/16/26

Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird

Andrew Mok CFA

Barclays

$480→$457

Buy

41.46%

Upside

Reiterated

07/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (NYSE: ELV) and Pfizer (NYSE: PFE)

Amit Daryanani

Evercore ISI

―

Hold

―

Reiterated

07/15/26

Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health

Erin Wright

Morgan Stanley

$404

Hold

25.06%

Upside

Reiterated

07/15/26

Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook

Ben Hendrix

RBC Capital

$439→$424

Hold

31.25%

Upside

Reiterated

07/15/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)

Scott Fidel

Goldman Sachs

$370→$395

Hold

22.27%

Upside

Reiterated

07/15/26

Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs

Jason Cassorla

Guggenheim

$399→$455

Buy

40.85%

Upside

Reiterated

07/15/26

Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)

Ryan Langston

TD Cowen

$465

Buy

43.94%

Upside

Assigned

07/14/26

TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)

Ann Hynes

Mizuho Securities

$465→$470

Buy

45.49%

Upside

Reiterated

07/13/26

Mizuho Securities Keeps Their Buy Rating on Elevance Health (ELV)

Sarah James

Cantor Fitzgerald

$400→$450

Buy

39.30%

Upside

Reiterated

07/07/26

Elevance Health price target raised to $450 from $400 at Cantor FitzgeraldElevance Health price target raised to $450 from $400 at Cantor Fitzgerald

Lance Wilkes

Bernstein

$424→$482

Buy

49.20%

Upside

Reiterated

07/02/26

Elevance Health price target raised to $482 from $424 at BernsteinElevance Health price target raised to $482 from $424 at Bernstein

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TARAProtara Therapeutics

BKDBrookdale Senior Living

EYPTEyePoint Pharmaceuticals

ZVRAZevra Therapeutics

DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months

George HillDeutsche Bank

Success Rate

12/18 ratings generated profit

Average Return

+4.06%

Copying George Hill's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +4.06% per trade.

1 Year

A.J. RiceUBS

Success Rate

25/31 ratings generated profit

Average Return

+20.09%

Copying A.J. Rice's trades and holding each position for 1 Year would result in 80.65% of your transactions generating a profit, with an average return of +20.09% per trade.

2 Years

A.J. RiceUBS

Success Rate

29/31 ratings generated profit

Average Return

+40.84%

Copying A.J. Rice's trades and holding each position for 2 Years would result in 93.55% of your transactions generating a profit, with an average return of +40.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ELV has received 29 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 447.28.

Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $4.84 with a range of $4.55 to $5.53. The previous quarter’s EPS was $7.45. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $49.25B with a range of $47.79B to $51.00B. The previous quarter’s sales results were $50.47B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?

Based on analyst ratings, Elevance Health, Inc.’s 12-month average price target is 447.28.

What is ELV’s upside potential, based on the analysts’ average price target?

Elevance Health, Inc. has 38.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ELV a Buy, Sell or Hold?

Elevance Health, Inc. has a consensus rating of Moderate Buy which is based on 13 buy ratings, 6 hold ratings and 0 sell ratings.

What is Elevance Health, Inc.’s price target?

The average price target for Elevance Health, Inc. is 447.28. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $498.00 ,the lowest forecast is $364.00. The average price target represents 38.45% Increase from the current price of $323.05.

What do analysts say about Elevance Health, Inc.?

Elevance Health, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of ELV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Elevance Health (ELV) Stock Forecast & Price Target

ELV Analyst Ratings

ELV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Elevance Health

ELV Analyst Recommendation Trends

ELV Financial Forecast

ELV Earnings Forecast

ELV Sales Forecast

ELV Stock Forecast FAQ

Detailed List of Analyst Forecasts